2004 discharge: European Agency for the Evaluation of Medicinal Products

This procedure concerns the European Agency for the Evaluation of Medicinal Products (EMEA) and its budget for the financial year 2004. It involves the European Parliament's decision on whether to grant discharge, essentially approving the agency's accounts and management.

This decision affects the EMEA and its financial accountability. It ensures transparency and proper use of public funds by the agency, which plays a key role in evaluating medicinal products within the EU.